About AEterna Zentaris (NASDAQ:AEZS)
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:AEZS
- CUSIP: N/A
- Web: www.aezsinc.com
Capitalization:- Market Cap: $12.32 million
- Outstanding Shares: 14,333,000
Average Prices:- 50 Day Moving Avg: $2.11
- 200 Day Moving Avg: $2.93
- 52 Week Range: $0.78 - $5.59
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.56
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $930,000.00
- Price / Sales: 13.25
- Book Value: $0.39 per share
- Price / Book: 2.22
Profitability:- EBIDTA: ($27,830,000.00)
- Net Margins: -3,773.91%
- Return on Equity: -213.27%
- Return on Assets: -65.19%
Debt:- Current Ratio: 3.98%
- Quick Ratio: 3.98%
Misc:- Average Volume: 342,854 shs.
- Beta: 1.68
- Short Ratio: 2.93
Frequently Asked Questions for AEterna Zentaris (NASDAQ:AEZS)
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings data on Monday, May, 8th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.85 million. AEterna Zentaris had a negative return on equity of 213.27% and a negative net margin of 3,773.91%. AEterna Zentaris's revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.37) earnings per share. View AEterna Zentaris' Earnings History.
Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?
3 brokerages have issued 12-month target prices for AEterna Zentaris' stock. Their predictions range from $2.00 to $6.00. On average, they expect AEterna Zentaris' share price to reach $3.67 in the next year. View Analyst Ratings for AEterna Zentaris.
What are analysts saying about AEterna Zentaris stock?
Here are some recent quotes from research analysts about AEterna Zentaris stock:
- 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (5/12/2017)
- 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include OHR Pharmaceutical (OHRP), Auris Medical Holding AG (EARS), Cytori Therapeutics (CYTX), Proteon Therapeutics (PRTO), Galena Biopharma (GALE), Eleven Biotherapeutics (EBIO), Eyegate Pharmaceuticals (EYEG), Aviragen Therapeutics (AVIR), Capricor Therapeutics (CAPR), CorMedix (CRMD), OncoSec Medical (ONCS), Anthera Pharmaceuticals (ANTH), Argos Therapeutics (ARGS), Catalyst Biosciences (CBIO), Repros Therapeutics (RPRX), GenVec (GNVC), Novus Therapeutics (NVUS) and Onconova Therapeutics (ONTX).
Who owns AEterna Zentaris stock?
Who sold AEterna Zentaris stock? Who is selling AEterna Zentaris stock?
Who bought AEterna Zentaris stock? Who is buying AEterna Zentaris stock?
How do I buy AEterna Zentaris stock?
Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AEterna Zentaris stock cost?
One share of AEterna Zentaris stock can currently be purchased for approximately $0.86.
Earnings History for AEterna Zentaris (NASDAQ:AEZS)Earnings History by Quarter for AEterna Zentaris (NASDAQ:AEZS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | 3/31/2017 | ($0.33) | ($0.31) | $0.85 million | $0.26 million | View | Listen |  |
| 3/15/2017 | 12/31/2016 | ($0.73) | ($0.71) | $0.40 million | $0.30 million | View | N/A | |
| 11/8/2016 | Q316 | ($0.74) | ($0.61) | $0.22 million | $0.27 million | View | Listen | |
| 5/9/2016 | Q216 | ($0.82) | ($0.71) | $0.50 million | $0.24 million | View | N/A | |
| 3/29/2016 | Q415 | ($1.30) | ($1.46) | $0.25 million | $0.10 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.06) | ($0.07) | $0.20 million | $0.17 million | View | N/A | |
| 8/13/2015 | Q215 | ($0.08) | ($0.14) | $0.55 million | $0.20 million | View | Listen | |
| 5/7/2015 | Q1 2015 | ($0.10) | ($0.13) | | $0.07 million | View | N/A | |
| 3/17/2015 | Q414 | ($0.16) | $0.06 | | $0.01 million | View | N/A | |
| 3/20/2014 | Q413 | ($0.04) | ($0.22) | $12.41 million | | View | N/A | |
| 3/21/2013 | Q412 | ($0.31) | ($0.29) | $7.96 million | $9.16 million | View | N/A | |
| 11/13/2012 | Q312 | ($0.43) | ($0.35) | $8.38 million | $7.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)Current Year EPS Consensus Estimate: $-1.3900 EPS
Next Year EPS Consensus Estimate: $-0.5500 EPS
Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for AEterna Zentaris (NASDAQ:AEZS)
Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
| Source: |
|
| Date | Headline |
|---|
 | Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock? - Nasdaq
www.nasdaq.com - May 22 at 3:22 PM |
 | Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock?
finance.yahoo.com - May 22 at 3:22 PM |
 | AEterna Zentaris Inc. (AEZS) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:40 PM |
| AEterna Zentaris Inc. (AEZS) Price Target Cut to $3.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 10 at 7:56 AM |
| Aeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting
finance.yahoo.com - May 9 at 8:23 PM |
| AEterna Zentaris Inc. (AEZS) Announces Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 9 at 1:38 PM |
| Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 8 at 8:21 PM |
 | AEterna Zentaris: Learning From Mistakes - Seeking Alpha
seekingalpha.com - May 5 at 3:23 PM |
| AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 5 at 9:46 AM |
| AEterna Zentaris (AEZS) Given News Sentiment Rating of 0.22
www.americanbankingnews.com - May 3 at 10:15 AM |
| Today's Research Reports on Stocks to Watch: AEterna Zentaris and Exelixis
finance.yahoo.com - May 2 at 3:25 PM |
| Aeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017
finance.yahoo.com - May 2 at 3:25 PM |
| Maxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $2.00 Price Target
www.americanbankingnews.com - May 1 at 9:48 PM |
 | IIROC Trading Halt - AEZS
www.bizjournals.com - May 1 at 3:21 PM |
 | Aeterna Zentaris (AEZS) Phase 3 Study of Zoptrex Doesn't Achieve Primary Endpoint
www.streetinsider.com - May 1 at 3:21 PM |
| Pre-Open Movers 05/01: (OCN) (XXII) (TWTR) Higher; (FNBC) (AEZS) (ITCI) Lower (more...) - StreetInsider.com
www.streetinsider.com - May 1 at 9:54 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-First NBC Bank, Twitter, Tribune Media, Aeterna Zentaris, Neurotrope - Nasdaq
www.nasdaq.com - May 1 at 9:54 AM |
| Aeterna Zentaris (AEZS) Phase 3 Study of Zoptrex Doesn't Achieve Primary Endpoint - StreetInsider.com
www.streetinsider.com - May 1 at 9:54 AM |
| Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint
finance.yahoo.com - May 1 at 9:53 AM |
| AEterna's stock plunges toward record low after cancer treatment fails in Phase 3 trial
finance.yahoo.com - May 1 at 9:53 AM |
| Somewhat Favorable Media Coverage Likely to Impact AEterna Zentaris (AEZS) Share Price
www.americanbankingnews.com - April 30 at 11:17 AM |
| Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex™
finance.yahoo.com - April 28 at 8:50 PM |
| Aeterna Zentaris +3% as it readies Zoptrex study announcement
seekingalpha.com - April 28 at 7:10 PM |
| Aeterna Zentaris to sell 2.24M common shares ATM; stock down 5% premarket
seekingalpha.com - April 28 at 8:04 AM |
| Aeterna Zentaris Announces Replacement At the Market Issuance Program
finance.yahoo.com - April 27 at 8:40 PM |
| AEterna Zentaris (AEZS) Earns Daily News Impact Rating of 0.17
www.americanbankingnews.com - April 26 at 2:10 PM |
| Somewhat Favorable Media Coverage Somewhat Likely to Impact AEterna Zentaris (AEZS) Stock Price
www.americanbankingnews.com - April 23 at 7:46 AM |
| Zacks: AEterna Zentaris Inc. (AEZS) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 20 at 11:25 AM |
| AEterna Zentaris (AEZS) Earns News Impact Score of 0.44
www.americanbankingnews.com - April 19 at 7:42 AM |
| AEterna Zentaris (AEZS) Receives Daily News Sentiment Score of 0.31
www.americanbankingnews.com - April 15 at 8:48 AM |
| AEterna Zentaris Inc. (AEZS) Short Interest Update
www.americanbankingnews.com - April 8 at 8:28 AM |
| AEterna Zentaris Inc. (AEZS) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 5 at 9:31 AM |
| Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders
finance.yahoo.com - April 3 at 3:32 PM |
| AEZS One Step Closer, AKTX To Report Data In April, CBIO On The ... - Nasdaq
www.nasdaq.com - March 31 at 3:28 PM |
| AEterna Zentaris: Worth The Risk - Seeking Alpha
seekingalpha.com - March 31 at 3:28 PM |
 | AEterna Zentaris (AEZS) Jumps on NDA
www.baystreet.ca - March 30 at 3:46 PM |
 | Aeterna Zentaris Intends to File NDA with Respect to Macrilen™ in Third Quarter of 2017
us.rd.yahoo.com - March 30 at 3:46 PM |
| AEterna Zentaris Inc. (AEZS) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - March 30 at 11:31 AM |
| Aeterna Zentaris Announces At the Market Issuance Program
us.rd.yahoo.com - March 28 at 8:21 PM |
| AETERNA ZENTARIS INC. Financials
finance.yahoo.com - March 22 at 3:23 PM |
| AEterna Zentaris Inc. (AEZS) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 16 at 10:43 AM |
| Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
us.rd.yahoo.com - March 15 at 8:29 PM |
| Maxim Group Reaffirms Buy Rating for AEterna Zentaris Inc. (AEZS)
www.americanbankingnews.com - March 8 at 2:21 PM |
| Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™
us.rd.yahoo.com - March 7 at 3:23 PM |
| Aeterna Zentaris (AEZS) Announces EMA Pediatric Committee ... - StreetInsider.com
www.streetinsider.com - March 7 at 3:23 PM |
| Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
finance.yahoo.com - March 6 at 10:13 AM |
| Aeterna Zentaris (AEZS) Announces Presentation Regarding Macrilen at Endocrine Society Meeting - StreetInsider.com
www.streetinsider.com - March 3 at 3:36 PM |
 | Aeterna Zentaris Announces Presentation Regarding Macrilen - Business Wire (press release)
www.businesswire.com - March 2 at 8:36 PM |
| Molina Healthcare (MOH) Issues Revised Q4 & 2016 Results - Yahoo Finance
finance.yahoo.com - March 2 at 3:34 PM |
| Is AEterna Zentaris Worth A Look?
seekingalpha.com - February 24 at 8:21 PM |
AEterna Zentaris (AEZS) Chart for Tuesday, May, 23, 2017
